BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth.
Share this article
Corporate
Score 55
Bullish
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth
Mar 21, 2026 01:39 UTC
IBRX
Long term
Related Articles
Score 72
Bullish
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Mar 21, 23:33
Score 25
Bullish
Why Scholastic Stock Climbed This Week
Mar 21, 23:27
Score 65
Bullish
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
Mar 21, 23:15
Score 75
Bullish
Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push
Mar 21, 23:03
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.